KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Assets (2016 - 2025)

Travere Therapeutics' Assets history spans 15 years, with the latest figure at $605.2 million for Q4 2025.

  • For Q4 2025, Assets rose 1.86% year-over-year to $605.2 million; the TTM value through Dec 2025 reached $605.2 million, up 1.86%, while the annual FY2025 figure was $605.2 million, 1.86% up from the prior year.
  • Assets reached $605.2 million in Q4 2025 per TVTX's latest filing, up from $538.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $832.8 million in Q3 2023 to a low of $504.4 million in Q3 2024.
  • Average Assets over 5 years is $689.8 million, with a median of $731.3 million recorded in 2022.
  • Peak YoY movement for Assets: surged 33.33% in 2021, then plummeted 39.44% in 2024.
  • A 5-year view of Assets shows it stood at $776.6 million in 2021, then fell by 13.4% to $672.6 million in 2022, then rose by 17.3% to $788.9 million in 2023, then decreased by 24.69% to $594.1 million in 2024, then grew by 1.86% to $605.2 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Assets are $605.2 million (Q4 2025), $538.6 million (Q3 2025), and $555.3 million (Q2 2025).